Max von Zedtwitz

“This is the book we wish existed before establishing our first international subsidiaries, to share with headquarters and guide our expansion.”Do you dream of building an international business? Are you planning to open subsidiaries in other countries? Has your company struggled in its attempts to go abroad? Expanding into foreign markets is a dream for many businessowners and executives. However, the journey from dream to success is a long and complex one, with many critical considerations and tough decisions to be made along the way. Internationalisation - From Dream to Success reveals the secrets of turning your international aspirations into reality. It offers insights into what to expect when you take your business abroad, the key steps you must take and the challenges that can arise – not only during the early days of internationalisation, but also in the years ahead. It answers a wealth of questions about the internationalisation process, including: • Why go abroad? • Which country should you choose? • What do customers in new markets want? • Who should you partner with? • How do you navigate cultural and legal differences? • How can you create an effective collaboration between the headquarters and the subsidiary? • And what is your role in all of this? Through compelling examples, supported by research and their own experiences, Claus Sehested and Max von Zedtwitz offer a clear path for anyone seeking success abroad. With over 20 years of experience as advisors to companies seeking to enter foreign markets, and having personally built businesses abroad as expatriate managers, the authors share everything they wish they had known before venturing out for the first time. This book is ideal for businessowners, top executives, expatriate managers, leaders, and employees who are facing an internationalisation process.Claus Sehested is an entrepreneur with a background as a specialist, expatriate manager, and co-founder in the manufacturing and service industries, along with over 20 years of experience as a partner in management consulting. He has lived, worked and studied in Europe, the US, the Middle East and Asia. Claus holds a PhD in Engineering from the Technical University of Denmark, and has also studied at the Technical University of Munich in Germany. In addition, he participated in international executive programmes to further enhance his expertise in global business leadership. Max Von Zedtwitz is a professor of international business and innovation at Copenhagen Business School (CBS). An expatriate for nearly 30 years in countries such as China, the United States, Russia, and Denmark, he has worked in academia, consulting and startup entrepreneurship, including at Tsinghua University in Beijing, SkolTech in Moscow, AsiaCompete in Hong Kong, IMD in Lausanne, PRTM in Shanghai and Harvard in the United States. He is presently also affiliated with Kaunas University of Technology in Lithuania and the Ecole Polytechnique in Paris. He has advised dozens of companies on internationalisation, especially in and from emerging markets, and has written extensively on global innovation, R&D and corporate incubation.

Dieses Buch untersucht und beleuchtet die wichtigsten Herausforderungen, denen sich die pharmazeutische Industrie in einem zunehmend wettbewerbsorientierten Umfeld mit inflationären F&E-Investitionen und verschärftem Kostendruck stellen muss. Die Autoren stellen drei Quellen der pharmazeutischen Innovation vor: neue Managementmethoden in der Arzneimittelentwicklung, neue Technologien als Voraussetzung für Spitzenforschung und -entwicklung und neue Formen der Zusammenarbeit und Internationalisierung, wie z. B. Open Innovation in den frühen Phasen der Forschung und Entwicklung. Neue Modelle und Methoden werden anhand von Fallbeispielen aus Europa, den USA und Asien illustriert. Diese dritte, vollständig überarbeitete Auflage wurde erweitert, um die neuesten Entwicklungen im Bereich der offenen und kollaborativen Innovation, die größere strategische Bedeutung von Risikokapital und Investitionen in der Frühphase sowie die neue Palette an aufkommenden Technologien, die jetzt in der pharmazeutischen Innovation eingesetzt werden, zu berücksichtigen.

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.

This book analyses the relationships among product safety strategy and culture, concurrent engineering, new product development (NPD) processes and product safety performance. Product safety is a matter of enormous economic and societal concern, given the safety risks to consumers and the financial risks to producers. Nevertheless, a thorough conceptual understanding of the effects of NPD policies and practices is still largely missing, as several large-scale trends have made clarifying the role of product safety in its socio-economic context difficult, including: the rise of consumerism and the shift in the balance of power from manufacturers to customers and regulators; the internationalization of value chains and the fragmentation of markets worldwide; and technological change leading to a sophistication of products that rendered average consumers increasingly unaware of risk and potential accidents. This volume sets out to close the gaps among research, practice and policy, with an emphasis on advocating responsible product innovation. Through an in-depth study of the durable juvenile products industry, the authors discover important relationships, for example that top management involvement, safety-first culture and robust NPD processes are paramount in increasing product safety and decreasing product recalls in firms. On the other end of the spectrum, concurrent engineering does not automatically lead to product safety, they found no “magic bullet” through which product safety can be tied to the use of a particular tool, skill, or practice. Offering a dynamic framework for aligning the interests of multiple stakeholders, including manufacturers, regulators, and consumers, the authors provide a clearer understanding of product safety and its implications for scholars, students, policy makers, and practitioners in the areas of innovation management, product management, R&D management, and responsible research and innovation.

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.

This book analyses the relationships among product safety strategy and culture, concurrent engineering, new product development (NPD) processes and product safety performance. Product safety is a matter of enormous economic and societal concern, given the safety risks to consumers and the financial risks to producers. Nevertheless, a thorough conceptual understanding of the effects of NPD policies and practices is still largely missing, as several large-scale trends have made clarifying the role of product safety in its socio-economic context difficult, including: the rise of consumerism and the shift in the balance of power from manufacturers to customers and regulators; the internationalization of value chains and the fragmentation of markets worldwide; and technological change leading to a sophistication of products that rendered average consumers increasingly unaware of risk and potential accidents. This volume sets out to close the gaps among research, practice and policy, with an emphasis on advocating responsible product innovation. Through an in-depth study of the durable juvenile products industry, the authors discover important relationships, for example that top management involvement, safety-first culture and robust NPD processes are paramount in increasing product safety and decreasing product recalls in firms. On the other end of the spectrum, concurrent engineering does not automatically lead to product safety, they found no “magic bullet” through which product safety can be tied to the use of a particular tool, skill, or practice. Offering a dynamic framework for aligning the interests of multiple stakeholders, including manufacturers, regulators, and consumers, the authors provide a clearer understanding of product safety and its implications for scholars, students, policy makers, and practitioners in the areas of innovation management, product management, R&D management, and responsible research and innovation.